1. Home
  2. DFIN vs MIRM Comparison

DFIN vs MIRM Comparison

Compare DFIN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFIN
  • MIRM
  • Stock Information
  • Founded
  • DFIN 1983
  • MIRM 2018
  • Country
  • DFIN United States
  • MIRM United States
  • Employees
  • DFIN N/A
  • MIRM N/A
  • Industry
  • DFIN Other Consumer Services
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • DFIN Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • DFIN Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • DFIN 1.9B
  • MIRM 1.9B
  • IPO Year
  • DFIN N/A
  • MIRM 2019
  • Fundamental
  • Price
  • DFIN $60.54
  • MIRM $41.09
  • Analyst Decision
  • DFIN Strong Buy
  • MIRM Strong Buy
  • Analyst Count
  • DFIN 3
  • MIRM 13
  • Target Price
  • DFIN $76.33
  • MIRM $56.23
  • AVG Volume (30 Days)
  • DFIN 184.8K
  • MIRM 277.2K
  • Earning Date
  • DFIN 10-31-2024
  • MIRM 11-15-2024
  • Dividend Yield
  • DFIN N/A
  • MIRM N/A
  • EPS Growth
  • DFIN 18.18
  • MIRM N/A
  • EPS
  • DFIN 3.18
  • MIRM N/A
  • Revenue
  • DFIN $802,100,000.00
  • MIRM $264,375,999.00
  • Revenue This Year
  • DFIN $3.69
  • MIRM $73.07
  • Revenue Next Year
  • DFIN $4.59
  • MIRM $27.98
  • P/E Ratio
  • DFIN $18.88
  • MIRM N/A
  • Revenue Growth
  • DFIN 1.74
  • MIRM 128.34
  • 52 Week Low
  • DFIN $52.52
  • MIRM $23.14
  • 52 Week High
  • DFIN $71.01
  • MIRM $45.23
  • Technical
  • Relative Strength Index (RSI)
  • DFIN 41.96
  • MIRM 59.06
  • Support Level
  • DFIN $56.02
  • MIRM $38.16
  • Resistance Level
  • DFIN $64.18
  • MIRM $41.15
  • Average True Range (ATR)
  • DFIN 1.85
  • MIRM 1.49
  • MACD
  • DFIN -0.59
  • MIRM 0.24
  • Stochastic Oscillator
  • DFIN 35.65
  • MIRM 63.91

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a global risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( US), Europe, Asia, Canada, and others, of which the US accounts for the vast majority of its total revenue.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: